Clinical Efiicacy of Marichyadi Lepa and Abhayarishta on Shvitra (Vitiligo)
Phase 2
- Conditions
- Health Condition 1: null- Patients having signs and symptoms of Shvitra (Vitiligo).
- Registration Number
- CTRI/2017/02/007929
- Lead Sponsor
- IPGT and RA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
Patients having signs and symptoms of Shvitra (leucoderma)
Patient between the age of 16 to 60 years
Patients with chronicity of less than 10 years
Exclusion Criteria
Patients with Chronicity more than 10 years
Patient below the age of 16 and above the age of 60 years
Patients having serious cardiac renal hepatic diseases major illness like IDDM NIDDM patches due to burning chemical explosion any other serious systemic illness
Gravid and lactating women
Cases with Asadhya Lakshanas of Shvitra
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method It is expected that the trial drugs will exert a <br/ ><br>significant improvement in combating shvitraTimepoint: The effect will be assessed on the basis of subjective and objective criteria <br/ ><br>Improvement in the signs and symptoms will be analysed on the basis of special adopted scoring pattern for scrutinizing the symptomatology <br/ ><br>The score will be given on the basis of site size colour numbers and chronicity of the patches etc
- Secondary Outcome Measures
Name Time Method By providing better effect on Shvitra,the drug will effect psychosomatic level of the <br/ ><br>enrolled patients, enhance quality of life and will <br/ ><br>contribute in reducing social stigma of the patients affecting with Shvitra. Overall improvement in the disease condition, <br/ ><br>Quality of Life of the diseased. <br/ ><br>Based on the observations, the trial drug may be <br/ ><br>recommended to be added into the Essential <br/ ><br>Drugs List of Ministry of AYUSH, New DelhiTimepoint: 18 Months of Trial